“These university-industry partnerships demonstrate the impact of how academic and private organizations in the community can join forces to leverage each other’s strengths to find solutions for complex scientific challenges and processes, and ultimately contribute to innovation and economic growth in the Buffalo Niagara region. ”
Christina Orsi, associate vice president for economic development
COVID-19 rapid diagnostic test kits and their reagents. A next-generation vaccine adjuvant platform. How to predict dosing of monoclonal antibodies. Air sterilization technology.
You may not be familiar with all of these terms and technologies, but if you or a loved one contracts COVID-19, they could be vital for prevention, diagnosis, treatment and recovery. And they are being developed right here in Western New York made possible, in part, through state funding leveraged by UB.
Lansing based Rheonix COVID-19 diagnostic test receives expanded FDA Emergency Use Authorization
This content is brought to you by the FingerLakes1.com Team. Support our mission by visiting www.patreon.com/fl1 or learn how you send us your local content here.
Rheonix Inc. announced today that the United States Food and Drug Administration (FDA) has issued an expanded Emergency Use Authorization (EUA) for the Rheonix COVID-19™ MDx Assay and now allows the use of saliva as an approved sample type. The fully automated sample-to-answer assay was initially authorized for use on a range of respiratory specimens under EUA on April 29, 2020.
UB industry partners step up to fight COVID-19
UB industry partners step up to fight COVID-19
Rheonix is a molecular diagnostics company working with UB. Richard Montagna (left), senior vice president for scientific and clinical affairs at Rheonix, with UB’s Michael Buck, associate professor of biochemistry.
By Jessica Szklany
Empire State Development Acting Commissioner, and President and CEO-designate Eric Gertler
SUNY Chancellor Jim Malatras
“The recent partnerships between University at Buffalo and local organizations in health care is yet another example of SUNY’s strength in working collaboratively with industry leaders to solve for problems and overcome obstacles caused by COVID-19. ”